Non-invasive detection of gastric cancer by detecting the methylation of Reprimo-like in the blood
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 5, 2023
Grant Date -
Aug 19, 2021
app pub date -
Jun 20, 2018
filing date -
Jun 20, 2018
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The invention aims at a non-invasive method of early diagnosis of gastric cancer, using as a biomarker the levels of methylation of the DNA sequence of the promoter of the Reprimo-like gene in plasma. The inventors have established the utility of Reprimo-like as a biomarker, and especially as a biomarker for the early detection of gastric cancer, since they have determined that Reprimo-like is consistently silenced in gastric cancer, both in incipient and advanced stages. This silencing is given by methylation of its promoter region, which is detectable in plasma samples, allowing us to measure it as a liquid biopsy in a non-invasive, fast and inexpensive way.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully